Evercore ISI Group Upgrades Health Catalyst to Outperform, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Elizabeth Anderson upgraded Health Catalyst (HCAT) from In-Line to Outperform and increased the price target from $9 to $11.
January 03, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Health Catalyst's stock rating was upgraded by Evercore ISI Group from In-Line to Outperform, and the price target was raised from $9 to $11.
Upgrades by analysts, especially from a reputable firm like Evercore ISI Group, can lead to increased investor confidence and a potential short-term rise in the stock price. The raised price target from $9 to $11 suggests a positive outlook on the company's future performance, which may attract more buyers to the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100